Columbus, Ohio – A new study led by researchers at The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Solove Research Institute (OSUCCC – James) has identified a protein within certain immune cells that is required for optimal immune responses to cancer. The findings, reported in the journal Science Advances,...
Tag: <span>inhibitor</span>
Post
Antidepressant fluoxetine (Prozac) suppresses replication of SARS-CoV-2
By Sally Robertson, B.Sc A study conducted by researchers at Julius-Maximilians-Universität Würzburg has shown that the antidepressant agent fluoxetine may be an effective drug for the early treatment of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) among at-risk groups. Jochen Bodem and colleagues found that the selective serotonin reuptake inhibitor (SSRI) fluoxetine significantly inhibited viral...
Post
New nanoparticle drug combination for atherosclerosis
THE KOREA ADVANCED INSTITUTE OF SCIENCE AND TECHNOLOGY (KAIST) CREDIT: PROFESSOR JI-HO PARK, KAIST Physicochemical cargo-switching nanoparticles (CSNP) designed by KAIST can help significantly reduce cholesterol and macrophage foam cells in arteries, which are the two main triggers for atherosclerotic plaque and inflammation. The CSNP-based combination drug delivery therapy was proved to exert cholesterol-lowering, anti-inflammatory,...
Post
Existing drugs may limit damage caused by HIV
by Yale University Yale researchers have identified four drugs that may help minimize the long-term health effects of HIV infection, they report June 23 in the Journal of Clinical Investigation. Antiretroviral therapy has proved to be a life-saving treatment for those infected with HIV. Yet even after treatment, most patients still harbor latent HIV in...
Post
Acute kidney injury often seen with checkpoint inhibitor use
Harish Seethapathy, M.B.B.S., from Massachusetts General Hospital in Boston, and colleagues examined the frequency, severity, etiology, and predictors of AKI among patients receiving checkpoint inhibitor therapy from May 2011 to December 2016. Data were included for 1,016 patients (average age, 63 years). The researchers found that overall, 17 percent of patients receiving checkpoint inhibitor therapy...
Post
Additional inhibitor can help anti-VEGF therapy overcome resistance in deadly brain cancer
Penn study identifies target, shows proof-of-concept in mice UNIVERSITY OF PENNSYLVANIA SCHOOL OF MEDICINE PHILADELPHIA – Adding another inhibitor to therapies that cut off a tumor’s access to blood vessels could be the key to helping those therapies overcome resistance in glioblastoma, a deadly form of brain cancer. Drugs that target the vascular endothelial growth...
- 1
- 2